Alliance Foundation Trials, LLC (AFT) today announced the publication of the pivotal phase III PATINA study (AFT-38) in the New England Journal of Medicine (NEJM), marking a major milestone for patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) advanced breast cancer (ABC). The study’s results demonstrate that the addition of the CDK4/6 inhibitor palbociclib to standard first-line maintenance therapy significantly prolongs progression-free survival (PFS) by more than 15 months compared with standard therapy alone.

Deadly PM 2.5 air pollution that crosses state and national borders remains a serious global health issue. New research from the University of Notre Dame provides a tool to track responsibility and inform policy.

In a small study, dogs experienced both stabilization and destabilization of their balance upon hearing angry or happy human voices, but angry voices were linked to the biggest destabilizing effects. Nadja Affenzeller and colleagues at the University of Veterinary Medicine, Vienna, Austria, present these findings in the open-access journal PLOS One on January 28, 2026.

Professor Nisreen Alwan calls to de-stigmatize self-reported data in health care research, highlighting Long COVID as one setting where it has unique strengths over 'objective' data.